Adequacy of biopsy samples for epidermal growth factor receptor (EGFR) molecular testing in lung adenocarcinoma

Dragana  Tegeltija; Aleksandra Lovrenski; Tijana Vasiljević; Bojana Andrejić-Višnjić

doi:10.2298/VSP181225083T

Dragana Tegeltija Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia
Aleksandra Lovrenski Institute for Lung Diseases of Vojvodina, Sremska Kamenica, Serbia
Tijana Vasiljević University of Novi Sad, Faculty of Medicine, Department of Pathology, Novi Sad, Serbia
Bojana Andrejić-Višnjić University of Novi Sad, Faculty of Medicine, Department of Histology and Embryology, Novi Sad, Serbia

DOI: https://doi.org/10.2298/VSP181225083T

Keywords: lung neoplasms, adenocarcinoma, biopsy, erbb receptors, mutation

Abstract

Background/Aim. Adenocarcinoma of the lung is the most common histological type of lung cancer. The most reliable method in detecting epidermal growth factor receptor (EGFR) mutations is real-time polymerase chain reaction (PCR). It is recommended to sample three to five biopsy samples with a minimum of 200–400 preserved tumor cells. We analyzed the suitability of biopsy samples for EGFR molecular testing in lung adenocarcinoma. Methods. This retrospective analysis included 60 patients diagnosed with lung adenocarcinoma at the Institute for Pulmonary Diseases in Sremska Kamenica, Serbia from 2010 to 2015. Biopsy samples were obtained using transbronchial, bronchoscopic, or catheter biopsy procedures. All cases included the identification of morphometric parameters, the concentration of isolated DNA, and EGFR mutations. The proportion of tumors in biopsy samples was assessed in histological sections using computer-aided morphometry. Results. Biopsy samples were most commonly obtained by transbronchial biopsy (63%). In 35% of cases, there was either one or two biopsy samples. More than 10% of tumor cells were found in 68% of cases, while the majority of cases (33%) had between 200 and 500 tumor cells and only 8% of cases had between 20 and 50 tumor cells. The average concentration of DNA in all analyzed samples was 5.81 ng/µL and was significantly lower in samples provided by catheter biopsy. Only two cases with mutations were detected, and there was no statistically significant difference between the concentrations of isolated DNA in the wild type and mutated EGFR adenocarcinoma. Invalid results were found in 10% of cases. Conclusion. Biopsy samples are suitable for EGFR molecular testing in lung adenocarcinoma.

References

Adler I. Primary malignant growths of the lungs and bronchi. 1st ed. New York: Longmans, Green and Co; 1912.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0. Lyon, France: IARC CancerBase No. 11; 2012.

Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L. Correlation of sur-vival and EGFR mutation with predominant histologic sub-type according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol 2014; 12: 148.

Yu HA, Pao W. Targeted therapies: Afatinib-new therapy op-tion for EGFR-mutant lung cancer. Nat Rev Clin Oncol 2013; 10(10): 551‒2.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open la-bel, randomised phase 3 trial. Lancet Oncol 2010; 11(2):121‒8.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123‒32.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocar-cinoma. N Engl J Med 2009; 361(10): 947‒57.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giac-cone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, Interna-tional Association for the Study of Lung Cancer, and Associa-tion for Molecular Pathology. Arch Pathol Lab Med 2013; 137(6): 828–60.

Ofiara LM, Navasakulpong A, Beaudoin S, Gonzales AV. Opti-mizing tissue sampling for the diagnosis, subtyping, and mo-lecular analysis of lung cancer. Front Oncol 2014; 4: 253.

Zhuang YP, Wang HY, Shi MQ, Zhang J, Feng Y. Use of CT-guided fine needle aspiration biopsy in epidermal growth fac-tor receptor mutation analysis in patients with advanced lung cancer. Acta Radiol 2011; 52(10): 1083‒7.

Allegrini S, Antona J, Mezzapelle R, Miglio U, Paganotti A, Veg-giani C, et al. Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. Am J Clin Pathol 2012; 138(3): 377‒81.

Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9(2): 154‒62.

Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26(6): 983‒94.

Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, et al. A comparison of ARMS and DNA sequencing for mu-tation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010; 29: 132.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011; 6(2): 244‒85.

Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jara-millo AM, et al. International study to evaluate PCR methods for detection of trypanosoma cruzi DNA in blood samples from chagas disease patients. PLoS Neglect Trop D 2011; 5(1): e931.

Cikota B, Janezić A, Magić Z. Quantification of gene expression using the polymerase chain reaction. Vojnosanit Pregl 2002; 59(5): 551‒6. (Serbian)

Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer 2014; 120(18): 2883‒92.

El-Basmy A. Profile of lung cancer in Kuwait. Asian Pac J Cancer Prev 2013; 14(10): 6181‒4.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277‒300.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japa-nese patients. J Thorac Oncol 2013; 8(1): 52‒61.

Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, et al. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project-part. J Thorac Oncol 2011; 6(6): 1006‒15.

Stojšić J, Adzić T, Marić D, Subotić D, Milovanović I, Milenković B, et al. Histological types and age distribution of lung cancer operated patients over a 20-year period: a pathohistological based study. Srp Arh Celok Lek 2011; 139(9‒10): 619‒24.

Paliogiannis P, Attene F, Cossu A, Defraia E, Porcu G, Carta A, et al. Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Mol Med Rep 2015; 12(1): 187‒91.

Zhu P, Pan Q, Wang M, Zhong W, Zhao J. Efficacy of broncho-scopic biopsy for the detection of epidermal growth factor re-ceptor mutations and anaplastic lymphoma kinase gene rear-rangement in lung adenocarcinoma. Thorac Cancer 2015; 6(6): 709‒14.

Alberg AJ, Ford JG, Samet JM. American College of Chest Phy-sicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(3 Suppl): 29S‒55S.

Dey A, Biswas D, Saha SK, Kundu S, Kundu S, Sengupta A. Com-parison study of clinicoradiological profile of primary lung cancer cases: an Eastern India experience. Indian J Cancer 2012; 49(1): 89‒95.

Hajmanoochehri F, Mohammadi N, Zohal MA, Sodagar A, Ebtehaj M. Epidemiological and clinicopathological characteristics of lung cancer in a teaching hospital in Iran. Asian Pac J Cancer Prev 2014; 15(6): 2495‒500.

Niu XM, Lu S. Acetylcholine receptor pathway in lung cancer: new twists to an old story. World J Clin Oncol 2014; 5(4): 667‒76.

Balaban G, Žikić T, Perin B, Čanak V, Kopitović I, Jovanović S. Operability of patients with central bronchial cancer and ate-lectasis. Pneumon 1998; 36(1‒4): 11‒4. (Serbian)

Gellert AR, Rudd RM, Sinha G, Geddes DM. Fiberoptic bron-choscopy: effect of multiple bronchial biopsies on diagnostic yield in bronchial carcinoma. Thorax 1982; 37(9): 684‒7.

Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicol-son MC, et al. Quantitative analysis of tumor in bronchial bi-opsy specimens. J Thorac Oncol 2010; 5(4): 448‒52.

Scarpino S, Pulcini F, Di Napoli A, Giubettini M, Ruco L. EGFR mutation testing in pulmonary adenocarcinoma: evaluation of tumor cell number and tumor percent in paraffin sections of 120 small biopsies. Lung Cancer 2015; 87(1): 8‒13.

Krawczyk P, Ramlau R, Chorostowska-Wynimko J, Powrózek T, Lewandowska MA, Limon J, et al. The efficacy of EGFR gene mutation testing in various samples from non small cell lung cancer patients: a multicenter retrospective study. J Cancer Res Clin Oncol 2015; 141(1): 61‒8.

Khode R, Larsen DA, Culbreath BC, Parrish S, Walker KL, Say-age-Rabie L, et al. Comparative study of epidermal growth fac-tor receptor mutation analysis on cythology smears and surgi-cal pathology specimens from primary and metastatic lung car-cinoma. Cancer Cytopathol 2013; 121(7): 361‒9.

Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo NJ, at al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-Asia Study (IPASS). Lung Can-cer 2014; 83(2): 174‒81.

Zaric B, Stojsic V, Kovacevic T, Sarcev T, Tepavac A, Jankovic R, et al. Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbian patients with lung adenocarcinoma. J Thorac Oncol 2014; 9(9): 1406‒10.